A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

NCT06293053 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis

Interventions

DRUG: Dupilumab

Sponsor

Sanofi

Collaborators

[object Object]